The price of EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT) shares last traded on Wall Street rose 17.30% to $10.85.
Based on available information, 8 analysts follow EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $55.00 and a low of $22.00, we find $30.00. Given the previous closing price of $9.25, this indicates a potential upside of 224.32 percent. EYPT stock price is now 57.74% away from the 50-day moving average and 120.77% away from the 200-day moving average. The market capitalization of the company currently stands at $398.52M.
Among analysts, 0 rate the stock a hold while 7 rate it a buy. Brokers who have rated the stock have averaged $31.75 as their price target over the next twelve months.
With the price target of $33, Robert W. Baird recently initiated with Outperform rating for EyePoint Pharmaceuticals Inc. (NASDAQ: EYPT).
In other news, Liu Ye, Director sold 1 shares of the company’s stock on May 30. The stock was sold for $6 at an average price of $6.00. Upon completion of the transaction, the Director now directly owns 3,010,721 shares in the company, valued at $32.67 million. Insiders disposed of 15,328 shares of company stock worth roughly $0.17 million over the past 1 year. A total of 0.10% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in EYPT stock. A new stake in EyePoint Pharmaceuticals Inc. shares was purchased by CORMORANT ASSET MANAGEMENT, LP during the first quarter worth $2,442,000. SQUAREPOINT OPS LLC invested $714,000 in shares of EYPT during the first quarter. In the first quarter, BRIDGEWAY CAPITAL MANAGEMENT, LLC acquired a new stake in EyePoint Pharmaceuticals Inc. valued at approximately $326,000. VONTOBEL HOLDING LTD. acquired a new stake in EYPT for approximately $210,000. PFS INVESTMENTS INC. purchased a new stake in EYPT valued at around $141,000 in the second quarter. In total, there are 116 active investors with 89.10% ownership of the company’s stock.
A candlestick chart of EyePoint Pharmaceuticals Inc. (NASDAQ: EYPT) showed a price of $9.37 on Thursday morning. During the past 12 months, EyePoint Pharmaceuticals Inc. has had a low of $2.19 and a high of $11.44. As of last week, the company has a debt-to-equity ratio of 0.44, a current ratio of 5.40, and a quick ratio of 5.20. The fifty day moving average price for EYPT is $6.96 and a two-hundred day moving average price translates $4.93 for the stock.
The latest earnings results from EyePoint Pharmaceuticals Inc. (NASDAQ: EYPT) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at -$0.56, beating analysts’ expectations of -$0.68 by 0.12. This compares to -$0.56 EPS in the same period last year. The company reported revenue of $7.68 million for the quarter, compared to $9.29 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -17.33 percent. For the current quarter, analysts expect EYPT to generate $51.92M in revenue.
EyePoint Pharmaceuticals Inc.(EYPT) Company Profile
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, engages in developing and commercializing therapeutics to enhance the lives of patients with serious eye disorders in the United States, China, and the United Kingdom. Its commercial products include YUTIQ for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU for the treatment of postoperative inflammation. The company’s pipeline leverages its Durasert technology for sustained intraocular drug delivery, including EYP-1901, an investigational sustained delivery intravitreal treatment that is in Phase 2 clinical trials. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
